Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
ln Vitro |
Hypaphorine inhibits LPS-induced phosphorylation of ERK, nuclear factor kappa beta ((NFκB), NFκB inhibitor IκBα, and IKKβ, as well as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) expression. It also prevents NFκB from translocating into the nucleus in LPS-treated RAW 264.7 cells.[1]
|
---|---|
ln Vivo |
A potential therapeutic agent for treating osteoclast-based bone loss is hypaphorine, which inhibits RANKL-induced osteoclastogenesis through a decrease in the phosphorylation of NF-κB p65, ERK, p38, and c-Jun N-terminal kinase (JNK), and ERK, p38, and p38 kinases.[2]
|
Cell Assay |
Incubating the cells in 2% serum medium for 24 hours prior to treatment stopped the cell growth. The indicated cells were then plated in 96-well culture plates at a density of 5×103 cells/well, stimulated with varying concentrations of vaccaria hypaphorine (6.25, 12.5, 25, 50, 100, 200 μM), and incubated for 24 hours at 37°C in a 5% COsub>2/sub> saturated humidity condition. Finally, at 540 nm, the optical density (OD) was determined.
|
Animal Protocol |
C57BL/6J mice induced by LPS
10 and 30 mg/kg
p.o.
|
References |
Molecular Formula |
C14H18N2O2
|
---|---|
Molecular Weight |
246.3049
|
Exact Mass |
246.14
|
Elemental Analysis |
C, 68.27; H, 7.37; N, 11.37; O, 12.99
|
CAS # |
487-58-1
|
Related CAS # |
487-58-1
|
Appearance |
Solid powder
|
SMILES |
C[N+](C)(C)[C@@H](CC1=CNC2=CC=CC=C21)C(=O)[O-]
|
InChi Key |
AOHCBEAZXHZMOR-ZDUSSCGKSA-N
|
InChi Code |
InChI=1S/C14H18N2O2/c1-16(2,3)13(14(17)18)8-10-9-15-12-7-5-4-6-11(10)12/h4-7,9,13,15H,8H2,1-3H3/t13-/m0/s1
|
Chemical Name |
(2S)-3-(1H-indol-3-yl)-2-(trimethylazaniumyl)propanoate
|
Synonyms |
Hypaphorine; Hypaforin; Tryptophan betaine; L-Hypaphorine
|
HS Tariff Code |
2934.99.03.00
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O: ~100 mg/mL (~406.0 mM)
DMSO: < 1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (406.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.0601 mL | 20.3004 mL | 40.6009 mL | |
5 mM | 0.8120 mL | 4.0601 mL | 8.1202 mL | |
10 mM | 0.4060 mL | 2.0300 mL | 4.0601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effects of different doses of Vaccaria hypaphorine (12.5, 25 and 50 μM), Dex (100 μM) and Asp (1 mM) on the mRNA expressions of TNF-α (a), IL-1β (b), IL-6 (c), IL-10 (d) and MCP-1(e) response to LPS (1 μg/ml)-treated RAW264.7 cells for 24 h in vitro. Values are mean ± S.D. BMC Complement Altern Med . 2017 Feb 20;17(1):120. td> |
Effects of different doses of Vaccaria hypaphorine (12.5, 25 and 50 μM), Dex (100 μM) and Asp (1 mM) on the TNF-α (a), IL-1β (b), IL-6 (c), PGE2 (d) expressions and NO production (e) response to LPS (1 μg/ml)-treated RAW264.7 cells for 24 h in vitro. BMC Complement Altern Med . 2017 Feb 20;17(1):120. td> |
Effects of different doses of Vaccaria hypaphorine (12.5, 25 and 50 μM for 24 h) on the protein expressions of NFκB、IκBα、IKKβ and their phosphorylated protein in response to LPS-stimulated RAW264.7 cells in vitro. BMC Complement Altern Med . 2017 Feb 20;17(1):120. td> |